| Title : Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation - Metafuni_2021_Blood.Adv__ |
| Author(s) : Metafuni E , Cavattoni IM , Lamparelli T , Raiola AM , Ghiso A , Galaverna F , Gualandi F , Di Grazia C , Dominietto A , Varaldo R , Signori A , Chiusolo P , Sora F , Giammarco S , Laurenti L , Sica S , Angelucci E , Bacigalupo A |
| Ref : Blood Adv , : , 2021 |
| Abstract : The aim of this study was to develop a predictive score for moderate-severe chronic graft-versus-host disease (cGVHD) on day +100 after allogeneic stem cell transplantation (HSCT). We studied 1292 patients allografted between 1990 and 2016, alive on day +100 after transplant, without cGvHD, and with full biochemistry laboratory values available. Patients were randomly assigned to a training and a validation cohort (ratio 1:1). In the training cohort, a multivariate analysis identified four independent predictors of moderate-severe cGvHD: gammaglutamyltransferase <=75 UI/l, creatinine <=1 mg/dl, cholinesterase >=4576 UI/l and albumin >=4 g/dl. A score of 1 was assigned to each variable, producing a low (0-1), intermediate (2-3) and high (4) score. The cumulative incidence (CI) of moderate-severe cGvHD was 12%, 20% and 52% (p<0.0001) in the training cohort, and 13%, 24% and 33% (p=0.002) in the validation cohort. The 5 year CI of transplant related mortality (TRM) was 5%, 14%, 27%(p<0.0001) and 5%, 16%, 31%(p<0.0001), respectively. The 5 year survival was 64%, 57%, 54%(p=0.009) and 70%, 59%, 42%(p=0.0008) in the two cohorts respectively . In conclusion, Day100 score predicts cGvHD, TRM and survival, and, if validated in a separate group of patients, could be considered for trials of pre-emptive therapy. |
| ESTHER : Metafuni_2021_Blood.Adv__ |
| PubMedSearch : Metafuni_2021_Blood.Adv__ |
| PubMedID: 34920451 |
Metafuni E, Cavattoni IM, Lamparelli T, Raiola AM, Ghiso A, Galaverna F, Gualandi F, Di Grazia C, Dominietto A, Varaldo R, Signori A, Chiusolo P, Sora F, Giammarco S, Laurenti L, Sica S, Angelucci E, Bacigalupo A (2021)
Day100 Score predicts moderate-severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation
Blood Adv
:
Metafuni E, Cavattoni IM, Lamparelli T, Raiola AM, Ghiso A, Galaverna F, Gualandi F, Di Grazia C, Dominietto A, Varaldo R, Signori A, Chiusolo P, Sora F, Giammarco S, Laurenti L, Sica S, Angelucci E, Bacigalupo A (2021)
Blood Adv
: